Dan Turner

Dan Turner has 30 years of experience as an entrepreneur, operating manager and investor. He founded Montreux Equity Partners and has been a General Partner and Managing Member with Montreux since 1993.

Mr. Turner has invested in companies across consumer, healthcare services, pharmaceuticals and technology sectors. Some of his previous investments include Paymap (acquired by First Data Corp), Peapod (IPO; acquired by Royal Ahold), and Great Lakes Health Plan (acquired by United Healthcare). Mr. Turner is a member of the Board of Directors of Avantis Medical, GC Aesthetics, Moksha8, Pure Life Renal, KNOW Foods, and Crown Laboratories, Inc. He is a member of the Advisory Board of the Lester Center, located at the Haas School of Business, University of California, Berkeley.

Mr. Turner previously served as Montreux’s representative to the Board of Directors of Glaukos (NYSE: GKOS), Tobira Therapeutics, Epirus Biopharmaceuticals (NASDAQ: EPRS), Renal CarePartners (sold to Ambulatory Services of America in 2011), Cerexa (sold to Forest Laboratories in 2007), NovaCardia (sold to Merck in 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson in 2005).

Mr. Turner started his career with Price Waterhouse in the high technology group. He later became the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Prior to founding Montreux Equity Partners, Mr. Turner was a Principal in the Turnaround Group for Berkeley International.

Mr. Turner holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant.